The Quantellect read.As of Nov 19, 2026, 3 active firms cover Akari Therapeutics PLC: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $1.00 to $30.00 (about 30.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $19.33 sits 181% above the current $6.88. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-2.09 next quarter toward $-8.65 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$19.33
+181.0% upside
Average target across 3 active firms as of Nov 19, 2026 vs $6.88 current
Highest Target$30.00
Average Target$19.33
Lowest Target$1.00
Detailed analyst forecasts for AKTX
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate AKTX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
AKTX EPS & revenue forecast
EPS · NEXT QUARTER
$-2.09
Range $-2.09 – $-2.09 · 1 analysts
Next period, 1 analysts expect Akari Therapeutics PLC to earn $-2.09 a share (range $-2.09 – $-2.09), versus $0.00 a year earlier. Full-year consensus is $-9.05, growing to $-8.65 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Akari Therapeutics PLC
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AKTX.
#1
Sean Lee
HC Wainwright & Co. · Rank #344
Buy
$27.00+292.4% to target
Overall win rate
40%
+ Follow
#2
Aydin Huseynov
Ladenburg Thalmann · Rank #564
Buy
$1.00-85.5% to target
Overall win rate
32%
+ Follow
#3
Jason McCarthy
Maxim Group · Rank #567
Buy
$30.00+336.0% to target
Overall win rate
30%
+ Follow
#4
James Molloy
Alliance Global Partners · Rank #587
Buy
$280.00+3969.8% to target
Overall win rate
25%
+ Follow
AKTX stock forecast FAQ
What is AKTX's average 12-month price target?+
The 3 active firms with a live target average $19.33 for Akari Therapeutics PLC over the next 12 months, ranging from a $30.00 high to a $1.00 low, as of Nov 19, 2026.
Is AKTX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for AKTX?+
The Street-high target is $30.00 (Maxim Group), and the Street-low is $1.00 (Ladenburg Thalmann). The average of all 3 active-firm targets is $19.33.
How many active Wall Street firms cover AKTX?+
3 active firms have a recognized rating on Akari Therapeutics PLC as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering AKTX?+
Among analysts who currently cover AKTX, Sean Lee of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #344). Their current call is Buy with a $27.00 target.
What is Akari Therapeutics PLC's projected EPS for next quarter?+
The consensus estimate is $-2.09 per share (range $-2.09 – $-2.09) across 1 analysts. Full-year EPS is projected at $-9.05, rising to $-8.65 the following year.
How much revenue is Akari Therapeutics PLC expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading AKTX lately?+
As of Nov 19, 2026, 3 of 3 active firms rate AKTX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AKTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.